Weight-based ribavirin with pegylated interferon alfa 2b: Benefits, risks, and the origin of the evidence [4] (multiple letters)

Gastroenterology

Volumn 124, Issue 7, 2003, Pages 2003-2004

  Hrachovec, Jennifer ^c   Patel, Pallavi ^a   Poynard, Thierry ^b   McHutchison, John ^b   Manns, Michael ^b   Trepo, Christian ^b   Lindsay, Karen ^b   Goodman, Zahary ^b   Albrecht, Janice ^b  

^a CENTER FOR HEALTH STUDIES   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ANEMIA; BODY WEIGHT; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HUMAN; LETTER; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TOXICITY; VIRUS LOAD;

EID: 0037606049     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00576-6     Document Type: Letter

References (6)

1. T. Poynard J. McHutchison M. Manns C. Trepo Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
2. M.P. Manns J.G. McHutchinson S.C. Gordon V.K. Ristgi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial Lancet 9286 2001 958 965
3. P. Glue R. Rouzier-Panis C. Raffanel R. Sabo A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group Hepatology 32 2000 647 653
4. Food and Drug Administration Center for Drug Evaluation and Research Meeting of the Antiviral Drugs Advisory Committee, December 12, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3819t1.doc. Last accessed August 15, 2002.
5. Marzella L. Biologic License Supplement: Peginterferon a-2b and Ribavirin for Treatment of Chronic Hepatitis. Available at: http://www.fda.gov/ohrms/dockets/ac/01/slides/3819s1_01_cber/sld001.htm. Last accessed August 15, 2002.
6. T. Poynard Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 1997 825 832